These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 19494795

  • 1. Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain.
    Babbar S, Marier JF, Mouksassi MS, Beliveau M, Vanhove GF, Chanda S, Bley K.
    Ther Drug Monit; 2009 Aug; 31(4):502-10. PubMed ID: 19494795
    [Abstract] [Full Text] [Related]

  • 2. Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain.
    Simpson DM, Gazda S, Brown S, Webster LR, Lu SP, Tobias JK, Vanhove GF, NGX-4010 C118 Study Group.
    J Pain Symptom Manage; 2010 Jun; 39(6):1053-64. PubMed ID: 20538187
    [Abstract] [Full Text] [Related]

  • 3. An open-label pilot study of high-concentration capsaicin patch in painful HIV neuropathy.
    Simpson DM, Estanislao L, Brown SJ, Sampson J.
    J Pain Symptom Manage; 2008 Mar; 35(3):299-306. PubMed ID: 17959343
    [Abstract] [Full Text] [Related]

  • 4. NGX-4010, a high-concentration capsaicin dermal patch for lasting relief of peripheral neuropathic pain.
    Noto C, Pappagallo M, Szallasi A.
    Curr Opin Investig Drugs; 2009 Jul; 10(7):702-10. PubMed ID: 19579176
    [Abstract] [Full Text] [Related]

  • 5. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
    Int J Toxicol; 2007 Jul; 26 Suppl 1():3-106. PubMed ID: 17365137
    [Abstract] [Full Text] [Related]

  • 6. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomized, double-blind, controlled study with an open-label extension.
    Backonja MM, Malan TP, Vanhove GF, Tobias JK, C102/106 Study Group.
    Pain Med; 2010 Apr; 11(4):600-8. PubMed ID: 20113411
    [Abstract] [Full Text] [Related]

  • 7. NGX-4010, a capsaicin 8% dermal patch, administered alone or in combination with systemic neuropathic pain medications, reduces pain in patients with postherpetic neuralgia.
    Irving G, Backonja M, Rauck R, Webster LR, Tobias JK, Vanhove GF.
    Clin J Pain; 2012 Feb; 28(2):101-7. PubMed ID: 21753727
    [Abstract] [Full Text] [Related]

  • 8. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study.
    Backonja M, Wallace MS, Blonsky ER, Cutler BJ, Malan P, Rauck R, Tobias J, NGX-4010 C116 Study Group.
    Lancet Neurol; 2008 Dec; 7(12):1106-12. PubMed ID: 18977178
    [Abstract] [Full Text] [Related]

  • 9. A multicenter, randomized, double-blind, controlled dose finding study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia.
    Webster LR, Malan TP, Tuchman MM, Mollen MD, Tobias JK, Vanhove GF.
    J Pain; 2010 Oct; 11(10):972-82. PubMed ID: 20655809
    [Abstract] [Full Text] [Related]

  • 10. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy.
    Simpson DM, Brown S, Tobias J, NGX-4010 C107 Study Group.
    Neurology; 2008 Jun 10; 70(24):2305-13. PubMed ID: 18541884
    [Abstract] [Full Text] [Related]

  • 11. Developmental toxicity study of pure trans-capsaicin in rats and rabbits.
    Chanda S, Sharper V, Hoberman A, Bley K.
    Int J Toxicol; 2006 Jun 10; 25(3):205-17. PubMed ID: 16717036
    [Abstract] [Full Text] [Related]

  • 12. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia.
    Irving GA, Backonja MM, Dunteman E, Blonsky ER, Vanhove GF, Lu SP, Tobias J, NGX-4010 C117 Study Group.
    Pain Med; 2011 Jan 10; 12(1):99-109. PubMed ID: 21087403
    [Abstract] [Full Text] [Related]

  • 13. Capsaicin 8% topical patch (Qutenza)--a review of the evidence.
    Jones VM, Moore KA, Peterson DM.
    J Pain Palliat Care Pharmacother; 2011 Jan 10; 25(1):32-41. PubMed ID: 21426216
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
    Joerger M, Huitema AD, Meenhorst PL, Schellens JH, Beijnen JH.
    Cancer Chemother Pharmacol; 2005 May 10; 55(5):488-96. PubMed ID: 15726371
    [Abstract] [Full Text] [Related]

  • 15. A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia.
    Watson CP, Tyler KL, Bickers DR, Millikan LE, Smith S, Coleman E.
    Clin Ther; 1993 May 10; 15(3):510-26. PubMed ID: 8364943
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Prospective, non-interventional study on the tolerability and analgesic effectiveness over 12 weeks after a single application of capsaicin 8% cutaneous patch in 1044 patients with peripheral neuropathic pain: first results of the QUEPP study.
    Maihofner C, Heskamp ML.
    Curr Med Res Opin; 2013 Jun 10; 29(6):673-83. PubMed ID: 23551064
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.